GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » Total Payout Ratio

Modalis Therapeutics (TSE:4883) Total Payout Ratio : 0.00 (As of Mar. 29, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Modalis Therapeutics's current Total Payout Ratio is 0.00.


Modalis Therapeutics Total Payout Ratio Historical Data

The historical data trend for Modalis Therapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modalis Therapeutics Total Payout Ratio Chart

Modalis Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Payout Ratio
Get a 7-Day Free Trial -17.02 6.37 0.10 0.02 0.31

Modalis Therapeutics Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Modalis Therapeutics's Total Payout Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Modalis Therapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Modalis Therapeutics's Total Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Modalis Therapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Modalis Therapeutics's Total Payout Ratio falls into.


;
;

Modalis Therapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Modalis Therapeutics's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 736.119 + 0) / -2390.607
=0.31

Modalis Therapeutics's Total Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -323.01
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Modalis Therapeutics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Modalis Therapeutics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Modalis Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.

Modalis Therapeutics Headlines

No Headlines